Broadcasting from ACC 2024: Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial
Use of empagliflozin did not lead to a significant reduction in the composite of hospitalizations for heart failure or all-cause mortality in patients at increased risk for heart failure after acute myocardial infarction, according to results of the EMPACT-MI trial.
Presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Session, results of the trial, which come less than 6 months after results of DAPA-MI were presented at the American Heart Association 2023 Scientific Sessions, detail a nonsignificant trend toward benefit with use of empagliflozin among this patient population driven by reductions in heart failure hospitalizations.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
